{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:55:39Z","timestamp":1791939339373,"version":"4.3.4"},"reference-count":201,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["31920230160"],"award-info":[{"award-number":["31920230160"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["31920230062"],"award-info":[{"award-number":["31920230062"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017619","name":"Northwest Minzu University","doi-asserted-by":"publisher","award":["xbmuyjrc2023014"],"award-info":[{"award-number":["xbmuyjrc2023014"]}],"id":[{"id":"10.13039\/501100017619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017619","name":"Northwest Minzu University","doi-asserted-by":"publisher","award":["xbmuyjrc2020021"],"award-info":[{"award-number":["xbmuyjrc2020021"]}],"id":[{"id":"10.13039\/501100017619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32260037"],"award-info":[{"award-number":["32260037"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.virol.2024.110042","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T11:25:01Z","timestamp":1709810701000},"page":"110042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["New perspective of small-molecule antiviral drugs development for RNA viruses"],"prefix":"10.1016","volume":"594","author":[{"given":"Shasha","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiya","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9647-2827","authenticated-orcid":false,"given":"Ruofei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2024.110042_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103595","article-title":"The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model","volume":"72","author":"Abdelnabi","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.virol.2024.110042_bib2","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2174\/1389450117666160101120822","article-title":"Computer aided drug design for multi-target drug design: SAR\/QSAR, molecular docking and pharmacophore methods","volume":"18","author":"Abdolmaleki","year":"2017","journal-title":"Curr. Drug Targets"},{"issue":"Suppl. 3","key":"10.1016\/j.virol.2024.110042_bib3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.37201\/req\/s03.03.2022","article-title":"Antiviral drugs against SARS-CoV-2","volume":"35","author":"Aiello","year":"2022","journal-title":"Rev. Espa\u00f1ola Quimioter."},{"key":"10.1016\/j.virol.2024.110042_bib4","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41586-021-04175-x","article-title":"Structures of the sigma(2) receptor enable docking for bioactive ligand discovery","volume":"600","author":"Alon","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.virol.2024.110042_bib5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1042\/BST20160182","article-title":"Iminosugar antivirals: the therapeutic sweet spot","volume":"45","author":"Alonzi","year":"2017","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.virol.2024.110042_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114554","article-title":"HIV nucleoside reverse transcriptase inhibitors","volume":"240","author":"Amblard","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.virol.2024.110042_bib7","doi-asserted-by":"crossref","first-page":"S627","DOI":"10.1093\/infdis\/jiy422","article-title":"Protein phosphatase 1-targeting small-molecule C31 inhibits ebola virus replication","volume":"218","author":"Ammosova","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2024.110042_bib8","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1128\/AAC.00543-16","article-title":"Large-scale screening and identification of novel ebola virus and marburg virus entry inhibitors","volume":"60","author":"Anantpadma","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2024.110042_bib9","article-title":"Structural insights into SARS-CoV-2 proteins","author":"Arya","year":"2020","journal-title":"J. Mol. Biol. 433, 166725"},{"key":"10.1016\/j.virol.2024.110042_bib10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.virol.2019.10.011","article-title":"Porcine deltacoronavirus (PDCoV) modulates calcium influx to favor viral replication","volume":"539","author":"Bai","year":"2020","journal-title":"Virology"},{"key":"10.1016\/j.virol.2024.110042_bib11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/bs.podrm.2022.11.003","article-title":"Remdesivir","volume":"48","author":"Bakheit","year":"2023","journal-title":"Profiles Drug Subst. Excipients Relat. Methodol."},{"key":"10.1016\/j.virol.2024.110042_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105820","article-title":"In-silico screening for identification of potential inhibitors against SARS-CoV-2 transmembrane serine protease 2 (TMPRSS2)","volume":"162","author":"Barge","year":"2021","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.virol.2024.110042_bib13","series-title":"Targeting SARS-COV2 Main Protease Using HTVS and Simulation Analysis: A Drug Repurposing Approach against COVID-19","author":"Bastikar","year":"2020"},{"key":"10.1016\/j.virol.2024.110042_bib14","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1042\/BCJ20210219","article-title":"Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp14 RNA cap methyltransferase","volume":"478","author":"Basu","year":"2021","journal-title":"Biochem. J."},{"key":"10.1016\/j.virol.2024.110042_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/v13010052","article-title":"A novel ebola virus VP40 matrix protein-based screening for identification of novel candidate medical Countermeasures","volume":"13","author":"Bennett","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2024.110042_bib16","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1073\/pnas.91.6.2235","article-title":"Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin","volume":"91","author":"Block","year":"1994","journal-title":"P Natl Acad Sci USA"},{"key":"10.1016\/j.virol.2024.110042_bib17","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1021\/acsmedchemlett.1c00140","article-title":"Potent SARS-CoV-2 mRNA cap methyltransferase inhibitors by bioisosteric replacement of methionine in SAM cosubstrate","volume":"12","author":"Bobileva","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.virol.2024.110042_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/ph14121243","article-title":"Discovery of SARS-CoV-2 Nsp14 and Nsp16 methyltransferase inhibitors by high-throughput virtual screening","volume":"14","author":"Bobrovs","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.virol.2024.110042_bib19","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.cell.2013.07.015","article-title":"Structural rearrangement of ebola virus VP40 begets multiple functions in the virus life cycle","volume":"154","author":"Bornholdt","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.virol.2024.110042_bib20","series-title":"Characterization of Proprotein Convertases and Their Involvement in Virus Propagation","author":"B\u00f6ttcher-Friebertsh\u00e4user","year":"2018"},{"key":"10.1016\/j.virol.2024.110042_bib21","doi-asserted-by":"crossref","first-page":"10262","DOI":"10.1128\/JVI.01360-08","article-title":"Small-molecule effectors of hepatitis B virus capsid assembly give insight into virus life cycle","volume":"82","author":"Bourne","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110042_bib22","doi-asserted-by":"crossref","first-page":"9372","DOI":"10.1073\/pnas.1201130109","article-title":"RNA 3'-end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10\/nsp14 exoribonuclease complex","volume":"109","author":"Bouvet","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.virol.2024.110042_bib23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41586-021-03491-6","article-title":"Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia","volume":"594","author":"Braga","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.virol.2024.110042_bib24","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.molcel.2021.01.035","article-title":"Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication","volume":"81","author":"Bravo","year":"2021","journal-title":"Mol. Cell."},{"key":"10.1016\/j.virol.2024.110042_bib25","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41586-022-05594-0","article-title":"FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2","volume":"615","author":"Brevini","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.virol.2024.110042_bib26","doi-asserted-by":"crossref","first-page":"7248","DOI":"10.1128\/JVI.00542-16","article-title":"Mutagenesis of S-Adenosyl-l-Methionine-Binding residues in coronavirus nsp14 N7-methyltransferase demonstrates differing requirements for genome translation and resistance to innate immunity","volume":"90","author":"Case","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110042_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpc.2020.106438","article-title":"Mechanistic insights of host cell fusion of SARS-CoV-1 and SARS-CoV-2 from atomic resolution structure and membrane dynamics","volume":"265","author":"Chakraborty","year":"2020","journal-title":"Biophys. Chem."},{"key":"10.1016\/j.virol.2024.110042_bib28","doi-asserted-by":"crossref","first-page":"6534","DOI":"10.1080\/07391102.2021.1886174","article-title":"In silico identification and validation of natural antiviral compounds as potential inhibitors of SARS-CoV-2 methyltransferase","volume":"40","author":"Chandra","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.virol.2024.110042_bib29","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3390\/v12080844","article-title":"Ion channels as therapeutic targets for viral infections: further discoveries and future perspectives","volume":"12","author":"Charlton","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2024.110042_bib30","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1080\/22221751.2022.2071175","article-title":"Virus-host interaction networks as new antiviral drug targets for IAV and SARS-CoV-2","volume":"11","author":"Chen","year":"2022","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.virol.2024.110042_bib31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12250-016-3726-4","article-title":"Molecular mechanisms of coronavirus RNA capping and methylation","volume":"31","author":"Chen","year":"2016","journal-title":"Virol. Sin."},{"key":"10.1016\/j.virol.2024.110042_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108254","article-title":"Furin inhibitors block SARS-CoV-2 spike protein cleavage to suppress virus production and cytopathic effects","volume":"33","author":"Cheng","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.virol.2024.110042_bib33","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.15190\/d.2022.10","article-title":"Remdesivir: the first FDA-approved anti-COVID-19 treatment for young children","volume":"10","author":"Chera","year":"2022","journal-title":"Discoveries"},{"key":"10.1016\/j.virol.2024.110042_bib34","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40409-018-0162-y","article-title":"Yellow fever in Africa and the Americas: a historical and epidemiological perspective","volume":"24","author":"Chippaux","year":"2018","journal-title":"J. Venom. Anim. Toxins Incl. Trop. Dis."},{"key":"10.1016\/j.virol.2024.110042_bib35","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1002\/elps.201900222","article-title":"High-throughput droplet-based microfluidics for directed evolution of enzymes","volume":"40","author":"Chiu","year":"2019","journal-title":"Electrophoresis"},{"key":"10.1016\/j.virol.2024.110042_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235030","article-title":"In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation","volume":"15","author":"Choudhary","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.virol.2024.110042_bib37","first-page":"785","article-title":"Coronaviruses exploit a host cysteine-aspartic protease for replication","volume":"609","author":"Chu","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.virol.2024.110042_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26133792","article-title":"High-throughput fluorescent assay for inhibitor screening of proteases from RNA viruses","volume":"26","author":"Cihlova","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.virol.2024.110042_bib39","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1093\/glycob\/cwaa091","article-title":"The iminosugars celgosivir, castanospermine and UV-4 inhibit SARS-CoV-2 replication","volume":"31","author":"Clarke","year":"2021","journal-title":"Glycobiology"},{"key":"10.1016\/j.virol.2024.110042_bib40","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for covid-19 - interim WHO solidarity trial results","volume":"384","author":"Consortium","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2024.110042_bib41","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.2165\/11204950-000000000-00000","article-title":"Lopinavir\/Ritonavir: a review of its use in the management of HIV-1 infection","volume":"70","author":"Croxtall","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.virol.2024.110042_bib42","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2165\/00003495-200363080-00004","article-title":"Lopinavir\/ritonavir: a review of its use in the management of HIV infection","volume":"63","author":"Cvetkovic","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.virol.2024.110042_bib43","doi-asserted-by":"crossref","first-page":"9748","DOI":"10.1021\/acsomega.2c08279","article-title":"Comprehending the structure, dynamics, and mechanism of action of drug-resistant HIV protease","volume":"8","author":"Dakshinamoorthy","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.virol.2024.110042_bib44","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.virol.2024.110042_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007072","article-title":"Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo","volume":"13","author":"de Freitas","year":"2019","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.virol.2024.110042_bib46","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.chembiol.2018.05.011","article-title":"Inhibition of flaviviruses by targeting a conserved pocket on the viral envelope protein","volume":"25","author":"de Wispelaere","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.virol.2024.110042_bib47","doi-asserted-by":"crossref","first-page":"9388","DOI":"10.1002\/slct.202001419","article-title":"Silico identification of potential inhibitors of ADP-ribose phosphatase of SARS-CoV-2 nsP3 by combining E-pharmacophore- and receptor-based virtual screening of database","volume":"5","author":"Debnath","year":"2020","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.virol.2024.110042_bib48","doi-asserted-by":"crossref","first-page":"8071","DOI":"10.1128\/JVI.00407-08","article-title":"Coronavirus nonstructural protein 16 is a cap-0 binding enzyme possessing (nucleoside-2'O)-methyltransferase activity","volume":"82","author":"Decroly","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110042_bib49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2018.03.003","article-title":"Favipiravir as a potential countermeasure against neglected and emerging RNA viruses","author":"Delang","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2024.110042_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115290","article-title":"Recent advances in the development of methyltransferase (MTase) inhibitors against (re)emerging arboviruses diseases dengue and Zika","volume":"252","author":"Delgado-Maldonado","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.virol.2024.110042_bib51","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1126\/science.1077215","article-title":"Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids","volume":"299","author":"Deres","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.virol.2024.110042_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094503","article-title":"Dysregulation of the renin-angiotensin-aldosterone system (RAA) in patients infected with SARS-CoV-2-possible clinical consequences","volume":"22","author":"Dettlaff-Pokora","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.virol.2024.110042_bib53","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1038\/s41467-018-04776-7","article-title":"The TRPV4 channel links calcium influx to DDX3X activity and viral infectivity","volume":"9","author":"Donate-Macian","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2024.110042_bib54","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.bbrc.2019.11.065","article-title":"Combinatorial screening of a panel of FDA-approved drugs identifies several candidates with anti-Ebola activities","volume":"522","author":"Du","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.virol.2024.110042_bib55","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s42269-021-00517-x","article-title":"In silico identification of compounds from Nigella sativa seed oil as potential inhibitors of SARS-CoV-2 targets","volume":"45","author":"Duru","year":"2021","journal-title":"Bull. Natl. Res. Cent."},{"key":"10.1016\/j.virol.2024.110042_bib56","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/COH.0000000000000713","article-title":"Lenacapavir: a first-in-class HIV-1 capsid inhibitor","volume":"17","author":"Dvory-Sobol","year":"2022","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.virol.2024.110042_bib57","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/S0140-6736(22)00454-8","article-title":"Host-targeting oral antiviral drugs to prevent pandemics","volume":"399","author":"Dwek","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2024.110042_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117592","article-title":"Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study","volume":"253","author":"Elfiky","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.virol.2024.110042_bib59","article-title":"Overview of high-throughput screening","volume":"9","author":"Entzeroth","year":"2009","journal-title":"Curr Protoc Pharmacol Chapter"},{"key":"10.1016\/j.virol.2024.110042_bib60","doi-asserted-by":"crossref","DOI":"10.3791\/62422-v","article-title":"High-throughput antiviral assays to screen for inhibitors of Zika virus replication","author":"Fernandes","year":"2021","journal-title":"J. Vis. Exp.176 10.3791\/62422"},{"key":"10.1016\/j.virol.2024.110042_bib61","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41467-020-20718-8","article-title":"The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery","volume":"12","author":"Fu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2024.110042_bib62","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.chom.2018.04.015","article-title":"A sialylated voltage-dependent Ca(2+) channel binds hemagglutinin and mediates influenza A virus entry into mammalian cells","volume":"23","author":"Fujioka","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.virol.2024.110042_bib63","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"10.1016\/j.virol.2024.110042_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.783040","article-title":"DNA engineering and hepatitis B virus replication","volume":"12","author":"Gan","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.virol.2024.110042_bib65","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1093\/jac\/dku091","article-title":"The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry","volume":"69","author":"Gehring","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.virol.2024.110042_bib66","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41392-021-00760-8","article-title":"CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma","volume":"6","author":"Geng","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.virol.2024.110042_bib67","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1055\/a-1296-7935","article-title":"Favipiravir and COVID-19: a simplified summary","volume":"71","author":"Ghasemnejad-Berenji","year":"2021","journal-title":"Drug Res."},{"key":"10.1016\/j.virol.2024.110042_bib68","first-page":"1077","article-title":"Pandemic preparedness","volume":"35","author":"Godshall","year":"2021","journal-title":"Infect. Dis. Clin."},{"key":"10.1016\/j.virol.2024.110042_bib69","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0304-4017(93)90218-C","article-title":"Doramectin--a potent novel endectocide","volume":"49","author":"Goudie","year":"1993","journal-title":"Vet. Parasitol."},{"key":"10.1016\/j.virol.2024.110042_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2022.101151","article-title":"Protein structure-based in-silico approaches to drug discovery: guide to COVID-19 therapeutics","volume":"91","author":"Gupta","year":"2023","journal-title":"Mol. Aspect. Med."},{"key":"10.1016\/j.virol.2024.110042_bib71","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41594-017-0010-8","article-title":"Structural biology of Zika virus and other flaviviruses","volume":"25","author":"Hasan","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.virol.2024.110042_bib72","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1177\/1060028020962424","article-title":"Fostemsavir: a novel attachment inhibitor for patients with multidrug-resistant HIV-1 infection","volume":"55","author":"Hiryak","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.virol.2024.110042_bib73","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41579-019-0233-2","article-title":"Therapeutic strategies to target the Ebola virus life cycle","volume":"17","author":"Hoenen","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.virol.2024.110042_bib74","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.virol.2024.110042_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/v14020174","article-title":"Targeting the virus capsid as a tool to fight RNA viruses","volume":"14","author":"Hozakova","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2024.110042_bib76","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/nar\/gkac1207","article-title":"Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal details of exoribonuclease activation and mRNA capping and provide starting points for antiviral drug development","volume":"51","author":"Imprachim","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.virol.2024.110042_bib77","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.3389\/fmicb.2019.01945","article-title":"A structure-function diversity survey of the RNA-dependent RNA polymerases from the positive-strand RNA viruses","volume":"10","author":"Jia","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.virol.2024.110042_bib78","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.virol.2024.110042_bib79","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202154305","article-title":"ADAM10 and ADAM17 promote SARS-CoV-2 cell entry and spike protein-mediated lung cell fusion","volume":"23","author":"Jocher","year":"2022","journal-title":"EMBO Rep."},{"key":"10.1016\/j.virol.2024.110042_bib80","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1089\/adt.2007.101","article-title":"HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus","volume":"5","author":"Johnston","year":"2007","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.virol.2024.110042_bib81","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.virol.2024.110042_bib82","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1021\/acs.jmedchem.2c01750","article-title":"Structure-based design of potent iminosugar inhibitors of endoplasmic reticulum alpha-glucosidase I with anti-SARS-CoV-2 activity","volume":"66","author":"Karade","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.virol.2024.110042_bib83","article-title":"Core protein-directed antivirals and importin \u03b2 can synergistically disrupt hepatitis B virus capsids","volume":"96","author":"Kim","year":"2021","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110042_bib84","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1038\/s41467-019-10280-3","article-title":"Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors","volume":"10","author":"Kirchdoerfer","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2024.110042_bib85","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020106275","article-title":"Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2","volume":"39","author":"Klemm","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.virol.2024.110042_bib86","doi-asserted-by":"crossref","first-page":"e4395","DOI":"10.1002\/pro.4395","article-title":"Crystal structure of SARS-CoV-2 nsp10-nsp16 in complex with small molecule inhibitors, SS148 and WZ16","volume":"31","author":"Klima","year":"2022","journal-title":"Protein Sci."},{"key":"10.1016\/j.virol.2024.110042_bib87","doi-asserted-by":"crossref","unstructured":"Knyazhanskaya, E., Morais, M.C., Choi, K.H., 2021. Flavivirus enzymes and their inhibitors. Enzymes. 49 (2021): 265-303.","DOI":"10.1016\/bs.enz.2021.07.006"},{"key":"10.1016\/j.virol.2024.110042_bib88","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2021107821","article-title":"TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect host cells","volume":"40","author":"Koch","year":"2021","journal-title":"EMBO J."},{"key":"10.1016\/j.virol.2024.110042_bib89","doi-asserted-by":"crossref","DOI":"10.3390\/cells10040853","article-title":"Assembly and entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2): evaluation using virus-like particles","volume":"10","author":"Kumar","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.virol.2024.110042_bib90","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrd2490","article-title":"Fresh from the pipeline: maraviroc","volume":"7","author":"Kuritzkes","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.virol.2024.110042_bib91","doi-asserted-by":"crossref","first-page":"4864","DOI":"10.1128\/JVI.00252-16","article-title":"Zika virus: new clinical syndromes and its emergence in the western hemisphere","volume":"90","author":"Lazear","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110042_bib92","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","article-title":"Therapeutic strategies for COVID-19: progress and lessons learned","volume":"22","author":"Li","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.virol.2024.110042_bib94","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1126\/science.abi9310","article-title":"Structural basis of mismatch recognition by a SARS-CoV-2 proofreading enzyme","volume":"373","author":"Liu","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.virol.2024.110042_bib95","article-title":"Bionics design of affinity peptide inhibitors for SARS-CoV-2 RBD to block SARS-CoV-2 RBD-ACE2 interactions","volume":"9","author":"Liu","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.virol.2024.110042_bib96","article-title":"Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition","volume":"118","author":"Liu","year":"2021","journal-title":"P Natl Acad Sci USA"},{"key":"10.1016\/j.virol.2024.110042_bib97","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.cell.2021.02.013","article-title":"Antivirals with common targets against highly pathogenic viruses","volume":"184","author":"Lu","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.virol.2024.110042_bib98","doi-asserted-by":"crossref","first-page":"33230","DOI":"10.1074\/jbc.M110.120014","article-title":"Molecular mapping of the RNA cap 2\u2032-O-methyltransferase activation interface between severe acute respiratory syndrome coronavirus nsp10 and nsp16","volume":"285","author":"Lugari","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.virol.2024.110042_bib99","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41586-019-0917-9","article-title":"Ultra-large library docking for discovering new chemotypes","volume":"566","author":"Lyu","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.virol.2024.110042_bib100","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1111\/cas.14618","article-title":"RNA-dependent RNA polymerase, RdRP, a promising therapeutic target for cancer and potentially COVID-19","volume":"111","author":"Machitani","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.virol.2024.110042_bib101","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01960-15","article-title":"Suppression of drug resistance in dengue virus","volume":"6","author":"Mateo","year":"2015","journal-title":"mBio"},{"key":"10.1016\/j.virol.2024.110042_bib102","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.coph.2016.07.015","article-title":"Hepatitis C virus NS3\/4a protease inhibitors","volume":"30","author":"McCauley","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.virol.2024.110042_bib103","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.slasd.2021.10.012","article-title":"Identification of potent small molecule inhibitors of SARS-CoV-2 entry","volume":"27","author":"Mediouni","year":"2022","journal-title":"SLAS Discov"},{"key":"10.1016\/j.virol.2024.110042_bib104","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.671263","article-title":"Current strategies of antiviral drug discovery for COVID-19","volume":"8","author":"Mei","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.virol.2024.110042_bib105","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.cell.2020.06.033","article-title":"SnapShot: enveloped virus entry","volume":"182","author":"Mercer","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.virol.2024.110042_bib106","doi-asserted-by":"crossref","DOI":"10.1093\/femsre\/fuaa057","article-title":"Molecular diversity of coronavirus host cell entry receptors","volume":"45","author":"Millet","year":"2021","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.virol.2024.110042_bib107","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.cell.2020.08.021","article-title":"Emerging pandemic diseases: how we got to COVID-19","volume":"182","author":"Morens","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.virol.2024.110042_bib108","doi-asserted-by":"crossref","DOI":"10.3390\/v12020190","article-title":"Nanoscale structure determination of murray valley encephalitis and powassan virus non-coding RNAs","volume":"12","author":"Mrozowich","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2024.110042_bib109","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2024.110042_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116415","article-title":"A short survey of dengue protease inhibitor development in the past 6 years (2015-2020) with an emphasis on similarities between DENV and SARS-CoV-2 proteases","volume":"49","author":"Murtuja","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.virol.2024.110042_bib111","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25143193","article-title":"High throughput virtual screening to discover inhibitors of the main protease of the coronavirus SARS-CoV-2","volume":"25","author":"Olubiyi","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.virol.2024.110042_bib112","doi-asserted-by":"crossref","DOI":"10.3390\/v15071465","article-title":"Cholesterol-lowering drugs as potential antivirals: a repurposing approach against flavivirus infections","volume":"15","author":"Osuna-Ramos","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2024.110042_bib113","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.antiviral.2018.10.024","article-title":"Ezetimibe inhibits dengue virus infection in Huh-7 cells by blocking the cholesterol transporter Niemann-Pick C1-like 1 receptor","volume":"160","author":"Osuna-Ramos","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2024.110042_bib114","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.virol.2024.110042_bib115","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s40265-022-01786-0","article-title":"Lenacapavir: first approval","volume":"82","author":"Paik","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.virol.2024.110042_bib116","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.03662-21","article-title":"N7-Methylation of the coronavirus RNA cap is required for maximal virulence by preventing innate immune recognition","volume":"13","author":"Pan","year":"2022","journal-title":"mBio"},{"key":"10.1016\/j.virol.2024.110042_bib117","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/j.xphs.2021.03.004","article-title":"Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2","volume":"110","author":"Peele","year":"2021","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.virol.2024.110042_bib118","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.bbamcr.2018.10.022","article-title":"Mining of Ebola virus entry inhibitors identifies approved drugs as two-pore channel pore blockers","volume":"1866","author":"Penny","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.virol.2024.110042_bib119","doi-asserted-by":"crossref","first-page":"28265","DOI":"10.1074\/jbc.M501020200","article-title":"The use of calnexin and calreticulin by cellular and viral glycoproteins","volume":"280","author":"Pieren","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.virol.2024.110042_bib120","article-title":"Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia","volume":"1","author":"Pizzorno","year":"2020","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.virol.2024.110042_bib121","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00060","article-title":"Repurposing of drugs as novel influenza inhibitors from clinical gene expression infection signatures","volume":"10","author":"Pizzorno","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.virol.2024.110042_bib122","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.909","article-title":"Molnupiravir: a new candidate for COVID-19 treatment","volume":"10","author":"Pourkarim","year":"2022","journal-title":"Pharmacol Res Perspe"},{"key":"10.1016\/j.virol.2024.110042_bib123","first-page":"1","article-title":"Scaffold identification and drug repurposing for finding potential Dengue envelope inhibitors through ligand-based pharmacophore model","author":"Priya","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.virol.2024.110042_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2022.105608","article-title":"Repurposing of antiviral drugs for COVID-19 and impact of repurposed drugs on the nervous system","volume":"168","author":"Punekar","year":"2022","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.virol.2024.110042_bib125","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.virol.2024.110042_bib126","volume":"vol. 54","author":"Raphael","year":"2020"},{"key":"10.1016\/j.virol.2024.110042_bib127","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nrd.2018.77","article-title":"Cryo-EM in drug discovery: achievements, limitations and prospects","volume":"17","author":"Renaud","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.virol.2024.110042_bib128","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejmech.2015.10.031","article-title":"Tryptophan dendrimers that inhibit HIV replication, prevent virus entry and bind to the HIV envelope glycoproteins gp120 and gp41","volume":"106","author":"Rivero-Buceta","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.virol.2024.110042_bib129","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1128\/AAC.00626-16","article-title":"Optimization of a class of tryptophan dendrimers that inhibit HIV replication leads to a selective, specific, and low-nanomolar inhibitor of clinical isolates of enterovirus A71","volume":"60","author":"Rivero-Buceta","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2024.110042_bib130","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.tips.2021.01.003","article-title":"Drug repurposing for rare diseases","volume":"42","author":"Roessler","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.virol.2024.110042_bib131","first-page":"48","article-title":"A short guide to electrophysiology and ion channels","volume":"20","author":"Rubaiy","year":"2017","journal-title":"J. Pharm. Pharmaceut. Sci."},{"key":"10.1016\/j.virol.2024.110042_bib132","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1056\/NEJMp2032369","article-title":"FDA approval of remdesivir - a step in the right direction","volume":"383","author":"Rubin","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2024.110042_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113850","article-title":"Assessing the potential of repurposing ion channel inhibitors to treat emerging viral diseases and the role of this host factor in virus replication","volume":"156","author":"Russell","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.virol.2024.110042_bib134","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41586-023-05905-z","article-title":"Computational approaches streamlining drug discovery","volume":"616","author":"Sadybekov","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.virol.2024.110042_bib135","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1126\/science.1258758","article-title":"Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment","volume":"347","author":"Sakurai","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.virol.2024.110042_bib136","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41556-021-00821-8","article-title":"BRD2 inhibition blocks SARS-CoV-2 infection by reducing transcription of the host cell receptor ACE2","volume":"24","author":"Samelson","year":"2022","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.virol.2024.110042_bib137","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1021\/acsinfecdis.2c00571","article-title":"Broad-spectrum small-molecule inhibitors targeting the SAM-binding site of flavivirus NS5 methyltransferase","volume":"9","author":"Samrat","year":"2023","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.virol.2024.110042_bib138","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2023.2204164","article-title":"A universal fluorescence polarization high throughput screening assay to target the SAM-binding sites of SARS-CoV-2 and other viral methyltransferases","volume":"12","author":"Samrat","year":"2023","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.virol.2024.110042_bib139","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens11030293","article-title":"Antiviral agents against flavivirus protease: prospect and future direction","volume":"11","author":"Samrat","year":"2022","journal-title":"Pathogens"},{"key":"10.1016\/j.virol.2024.110042_bib140","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1111\/febs.15815","article-title":"New targets for drug design: importance of nsp14\/nsp10 complex formation for the 3'-5' exoribonucleolytic activity on SARS-CoV-2","volume":"288","author":"Saramago","year":"2021","journal-title":"FEBS J."},{"key":"10.1016\/j.virol.2024.110042_bib141","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/cid\/ciac180","article-title":"Molnupiravir and nirmatrelvir-ritonavir: oral coronavirus disease 2019 antiviral drugs","volume":"76","author":"Saravolatz","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.virol.2024.110042_bib142","doi-asserted-by":"crossref","first-page":"12286","DOI":"10.1080\/07391102.2021.1971562","article-title":"Ebselen suitably interacts with the potential SARS-CoV-2 targets: an in-silico approach","volume":"40","author":"Sarkar","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.virol.2024.110042_bib143","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.31473","article-title":"Hepatitis B virus core protein allosteric modulators can distort and disrupt intact capsids","volume":"7","author":"Schlicksup","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.virol.2024.110042_bib144","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s00408-020-00408-4","article-title":"ACE2: the major cell entry receptor for SARS-CoV-2","volume":"198","author":"Scialo","year":"2020","journal-title":"Lung"},{"key":"10.1016\/j.virol.2024.110042_bib145","doi-asserted-by":"crossref","unstructured":"Shannon, A., Selisko, B., Le, N., Huchting, J., Touret, F., Piorkowski, G., Fattorini, V., Ferron, F., Decroly, E., Meier, C., Coutard, B., Peersen, O., Canard, B., 2020. Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase. bioRxiv.15,098731.","DOI":"10.1101\/2020.05.15.098731"},{"key":"10.1016\/j.virol.2024.110042_bib146","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s41061-023-00432-x","article-title":"Structure-based drug design of RdRp inhibitors against SARS-CoV-2","volume":"381","author":"Shehzadi","year":"2023","journal-title":"Top. Curr. Chem."},{"key":"10.1016\/j.virol.2024.110042_bib147","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity","volume":"587","author":"Shin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.virol.2024.110042_bib148","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202115695","article-title":"Inhibition of ACE2-spike interaction by an ACE2 binder suppresses SARS-CoV-2 entry","volume":"61","author":"Shin","year":"2022","journal-title":"Angew. Chem., Int. Ed."},{"key":"10.1016\/j.virol.2024.110042_bib149","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","article-title":"Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of ebola and emerging viruses","volume":"60","author":"Siegel","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.virol.2024.110042_bib150","doi-asserted-by":"crossref","first-page":"812","DOI":"10.2174\/1389557517666171002161325","article-title":"Back to (non-)Basics: an update on neutral and charge-balanced glycosidase inhibitors","volume":"18","author":"Simone","year":"2018","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.virol.2024.110042_bib151","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.slasd.2023.01.001","article-title":"High throughput screening for drugs that inhibit 3C-like protease in SARS-CoV-2","volume":"28","author":"Smith","year":"2023","journal-title":"Slas Discovery"},{"key":"10.1016\/j.virol.2024.110042_bib152","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.665379","article-title":"Identification and characterization of Zika virus NS5 methyltransferase inhibitors","volume":"11","author":"Song","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.virol.2024.110042_bib153","article-title":"Effectiveness of Favipiravir monotherapy in the treatment of COVID-19: real world data analysis from Thailand","volume":"11","author":"Srisubat","year":"2023","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"10.1016\/j.virol.2024.110042_bib154","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00426-20","article-title":"Ca(2+) ions promote fusion of Middle East respiratory syndrome coronavirus with host cells and increase infectivity","volume":"94","author":"Straus","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110042_bib155","doi-asserted-by":"crossref","first-page":"8138","DOI":"10.1073\/pnas.0409732102","article-title":"A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly","volume":"102","author":"Stray","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.virol.2024.110042_bib156","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3389\/fmicb.2020.01063","article-title":"Protein- and peptide-based virus inactivators: inactivating viruses before their entry into cells","volume":"11","author":"Su","year":"2020","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.virol.2024.110042_bib157","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.743147","article-title":"Host molecules regulating neural invasion of Zika virus and drug repurposing strategy","volume":"13","author":"Tan","year":"2022","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.virol.2024.110042_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2022.105246","article-title":"Human coronaviruses: origin, host and receptor","volume":"155","author":"Tang","year":"2022","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.virol.2024.110042_bib159","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.03830","article-title":"Dominant drug targets suppress the emergence of antiviral resistance","volume":"3","author":"Tanner","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.virol.2024.110042_bib160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.855496","article-title":"Molnupiravir and its antiviral activity against COVID-19","volume":"13","author":"Tian","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.virol.2024.110042_bib161","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax5866","article-title":"Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia","volume":"11","author":"Toots","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.virol.2024.110042_bib162","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1126\/science.add0875","article-title":"Inhibition of cellular RNA methyltransferase abrogates influenza virus capping and replication","volume":"379","author":"Tsukamoto","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.virol.2024.110042_bib163","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bsheal.2021.01.001","article-title":"Review of pharmacologic and immunologic agents in the management of COVID-19","volume":"3","author":"Ungogo","year":"2021","journal-title":"Biosaf Health"},{"key":"10.1016\/j.virol.2024.110042_bib164","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jip.2017.02.006","article-title":"Advances in the application of high-throughput sequencing in invertebrate virology","volume":"147","author":"van Aerle","year":"2017","journal-title":"J. Invertebr. Pathol."},{"key":"10.1016\/j.virol.2024.110042_bib165","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00473-12","article-title":"Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans","volume":"3","author":"van Boheemen","year":"2012","journal-title":"mBio"},{"key":"10.1016\/j.virol.2024.110042_bib166","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1146\/annurev-virology-110615-042238","article-title":"The structural biology of hepatitis B virus: form and function","volume":"3","author":"Venkatakrishnan","year":"2016","journal-title":"Annu Rev Virol"},{"key":"10.1016\/j.virol.2024.110042_bib167","doi-asserted-by":"crossref","DOI":"10.3390\/v10020076","article-title":"RNA dependent RNA polymerases: insights from structure, function and evolution","volume":"10","author":"Venkataraman","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2024.110042_bib168","doi-asserted-by":"crossref","first-page":"10112","DOI":"10.1074\/jbc.RA120.013422","article-title":"Resistance to excision determines efficiency of hepatitis C virus RNA-dependent RNA polymerase inhibition by nucleotide analogs","volume":"295","author":"Villalba","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.virol.2024.110042_bib169","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23594-y","article-title":"A metal ion orients SARS-CoV-2 mRNA to ensure accurate 2 '-O methylation of its first nucleotide","volume":"12","author":"Viswanathan","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2024.110042_bib170","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104917","article-title":"Targeting the multifunctional HBV core protein as a potential cure for chronic hepatitis B","volume":"182","author":"Viswanathan","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2024.110042_bib171","article-title":"Oxalic acid blocked the binding of spike protein from SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variants to human angiotensin-converting enzymes 2","volume":"18","author":"Wang","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.virol.2024.110042_bib172","doi-asserted-by":"crossref","first-page":"e01055","DOI":"10.1128\/JVI.01055-17","article-title":"Screening of FDA-approved drugs for inhibitors of Japanese encephalitis virus infection","volume":"91","author":"Wang","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110042_bib173","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1021\/acs.jmedchem.0c00067","article-title":"Targeting endoplasmic reticulum alpha-glucosidase I with a single-dose iminosugar treatment protects against lethal influenza and dengue virus infections","volume":"63","author":"Warfield","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.virol.2024.110042_bib174","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2016.03.001","article-title":"Inhibition of endoplasmic reticulum glucosidases is required for in vitro and in vivo dengue antiviral activity by the iminosugar UV-4","volume":"129","author":"Warfield","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2024.110042_bib175","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.virol.2024.110042_bib176","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1126\/science.abf4058","article-title":"Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A","volume":"371","author":"White","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.virol.2024.110042_bib177","first-page":"15, 043166","article-title":"Clinical benefit of remdesivir in rhesus macaques infected with","volume":"bioRxiv","author":"Williamson","year":"2020","journal-title":"SARS-CoV-2"},{"key":"10.1016\/j.virol.2024.110042_bib178","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.virol.2024.110042_bib179","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s13238-020-00764-0","article-title":"The two-stage interaction of Ebola virus VP40 with nucleoprotein results in a switch from viral RNA synthesis to virion assembly\/budding","volume":"13","author":"Wu","year":"2022","journal-title":"Protein Cell"},{"key":"10.1016\/j.virol.2024.110042_bib180","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-020-0184-0","article-title":"The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin","volume":"5","author":"Xia","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.virol.2024.110042_bib181","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","article-title":"Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion","volume":"30","author":"Xia","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.virol.2024.110042_bib182","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41423-020-0374-2","article-title":"Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein","volume":"17","author":"Xia","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.virol.2024.110042_bib183","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1128\/AAC.00976-09","article-title":"An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life","volume":"54","author":"Xie","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2024.110042_bib184","first-page":"86","article-title":"A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry","volume":"27","author":"Xu","year":"2021","journal-title":"bioRxiv."},{"key":"10.1016\/j.virol.2024.110042_bib185","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.slasd.2021.12.005","article-title":"A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry","volume":"27","author":"Xu","year":"2022","journal-title":"SLAS Discov"},{"key":"10.1016\/j.virol.2024.110042_bib186","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1016\/j.cell.2021.05.033","article-title":"Coupling of N7-methyltransferase and 3'-5' exoribonuclease with SARS-CoV-2 polymerase reveals mechanisms for capping and proofreading","volume":"184","author":"Yan","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.virol.2024.110042_bib187","article-title":"High throughput screening targeting the dengue NS3-NS5 interface identifies antivirals against dengue, Zika and West Nile viruses","volume":"11","author":"Yang","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.virol.2024.110042_bib188","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/aps.2015.108","article-title":"High throughput screening technologies for ion channels","volume":"37","author":"Yu","year":"2016","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.virol.2024.110042_bib189","article-title":"Efficacy of oseltamivir in the treatment of patients infected with Covid-19","volume":"77","author":"Zendehdel","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.virol.2024.110042_bib190","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s12250-020-00316-0","article-title":"Generation of A Stable GFP-reporter Zika virus system for high-throughput screening of Zika virus inhibitors","volume":"36","author":"Zhang","year":"2021","journal-title":"Virol. Sin."},{"key":"10.1016\/j.virol.2024.110042_bib191","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41421-020-00235-0","article-title":"Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension","volume":"6","author":"Zhang","year":"2020","journal-title":"Cell Discovery"},{"key":"10.1016\/j.virol.2024.110042_bib192","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1021\/acsinfecdis.8b00269","article-title":"Discovery of novel hepatitis B virus nucleocapsid assembly inhibitors","volume":"5","author":"Zhang","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.virol.2024.110042_bib193","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103581","article-title":"Computer-aided drug design in seeking viral capsid modulators","volume":"28","author":"Zhao","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.virol.2024.110042_bib194","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s13238-021-00836-9","article-title":"High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors","volume":"12","author":"Zhao","year":"2021","journal-title":"Protein & cell"},{"key":"10.1016\/j.virol.2024.110042_bib195","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1016\/j.ygeno.2020.07.044","article-title":"Probing antiviral drugs against SARS-CoV-2 through virus-drug association prediction based on the KATZ method","volume":"112","author":"Zhou","year":"2020","journal-title":"Genomics"},{"key":"10.1016\/j.virol.2024.110042_bib196","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106024","article-title":"Repurposing of the antihistamine mebhydrolin napadisylate for treatment of Zika virus infection","volume":"128","author":"Zhou","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.virol.2024.110042_bib197","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41421-020-0153-3","article-title":"Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2","volume":"6","author":"Zhou","year":"2020","journal-title":"Cell Discov"},{"key":"10.1016\/j.virol.2024.110042_bib198","article-title":"Repurposing of doramectin as a new anti-zika virus agent","volume":"1068","author":"Zhu","year":"2023","journal-title":"Viruses.15,"},{"key":"10.1016\/j.virol.2024.110042_bib199","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1128\/JVI.76.10.4848-4854.2002","article-title":"A small molecule inhibits and misdirects assembly of hepatitis B virus capsids","volume":"76","author":"Zlotnick","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110042_bib200","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.tim.2010.11.003","article-title":"Virus assembly, allostery and antivirals","volume":"19","author":"Zlotnick","year":"2011","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.virol.2024.110042_bib201","doi-asserted-by":"crossref","first-page":"9161","DOI":"10.1038\/s41598-023-35907-w","article-title":"Ebselen derivatives inhibit SARS-CoV-2 replication by inhibition of its essential proteins: PL(pro) and M(pro) proteases, and nsp14 guanine N7-methyltransferase","volume":"13","author":"Zmudzinski","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.virol.2024.110042_bib202","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses - drug discovery and therapeutic options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682224000631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682224000631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T01:55:20Z","timestamp":1762221320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682224000631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":201,"alternative-id":["S0042682224000631"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2024.110042","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New perspective of small-molecule antiviral drugs development for RNA viruses","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2024.110042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110042"}}